NCT04626128 - Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

October 13, 2022

Study Completion Date

October 13, 2022

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG

CLS-AX

injectable suspension of small molecule tyrosine kinase inhibitor (TKI)

DRUG

Anti-VEGF

Standard of care therapy used to block vascular endothelial growth factor

Trial Locations (11)

Cumberland Valley Retina Consultants, Hagerstown

Southeast Retina Center, Augusta

Center for Retina and Macular Disease, Winter Haven

Retina Consultants of Texas, The Woodlands

Retina Consultants of Texas, Bellaire

Retina Consultants of Texas, San Antonio

Austin Retina Associates, Austin

Retinal Consultants of Arizona, Phoenix

California Retina Consultants, Bakersfield

Northern California Retina Vitreous Associates Medical Group, LLC, Mountain View

Retinal Consultants Medical Group, Sacramento